TY - JOUR
T1 - Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma
T2 - Results in twenty-nine patients
AU - Zackheim, H. S.
AU - Kashani-Sabet, M.
AU - Hwang, Samuel T
PY - 1996
Y1 - 1996
N2 - Background: Most patients with erythrodermic cutaneous T-cell lymphoma (CTCL) have intense, generalized, refractory pruritus. In some large series the median survival was approximately 3 years. Objective: Our purpose was to review our experience with methotrexate in the treatment of 29 patients with erythrodermic CTCL observed for up to 129 months. Methods: This is a retrospective study. Data are presented in terms of response rates, freedom from treatment failure, and overall survival. Results: Twelve patients (41%) achieved complete remission, and five (17%) achieved partial remission for a total response rate of 58%. The median freedom from treatment failure was 31 months, and the median survival was 8.4 years. Side effects caused treatment failure in only two patients. Conclusion: Low-dose methotrexate is a valuable first-line treatment for the majority of patients with early to intermediate- stage erythrodermic CTCL.
AB - Background: Most patients with erythrodermic cutaneous T-cell lymphoma (CTCL) have intense, generalized, refractory pruritus. In some large series the median survival was approximately 3 years. Objective: Our purpose was to review our experience with methotrexate in the treatment of 29 patients with erythrodermic CTCL observed for up to 129 months. Methods: This is a retrospective study. Data are presented in terms of response rates, freedom from treatment failure, and overall survival. Results: Twelve patients (41%) achieved complete remission, and five (17%) achieved partial remission for a total response rate of 58%. The median freedom from treatment failure was 31 months, and the median survival was 8.4 years. Side effects caused treatment failure in only two patients. Conclusion: Low-dose methotrexate is a valuable first-line treatment for the majority of patients with early to intermediate- stage erythrodermic CTCL.
UR - http://www.scopus.com/inward/record.url?scp=0029913175&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029913175&partnerID=8YFLogxK
U2 - 10.1016/S0190-9622(96)80062-4
DO - 10.1016/S0190-9622(96)80062-4
M3 - Article
C2 - 8601652
AN - SCOPUS:0029913175
VL - 34
SP - 626
EP - 631
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
SN - 0190-9622
IS - 4
ER -